Clinical Trial Update: A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain

View source ↗

Summary

This document notes the completion of a first-line treatment study for newly diagnosed transplant-ineligible multiple myeloma in Spain, sponsored by Celgene.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Status: COMPLETED